Haematogenous osteomyelitis in children: epidemiology, classification, aetiology and treatment

Baker, Alexander D. L.; Macnicol, Malcolm F.

doi:10.1016/j.paed.2007.11.002

Cited by 19 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,[9][10][11] For comparison, the annual incidence in the United States is estimated at 1:5000. 10 There has been a worldwide fall in the incidence of AHO.…”

Section: Discussionmentioning

confidence: 99%

“…The main indications for surgery include failure to respond to antibiotics after 48 to 72 hours, frank pus on aspiration, intra-articular suppuration, or sequestered abscess. 6,7,9,41,42 With clinical or radiologic evidence of septic arthritis or abscess formation, we would proceed to surgery immediately. In our institutions drilling of the affected bone is not routine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric Acute Hematogenous Osteomyelitis

Street

Puna

Huang

et al. 2015

Journal of Pediatric Orthopaedics

View full text Add to dashboard Cite

show abstract

“…4,[9][10][11] For comparison, the annual incidence in the United States is estimated at 1:5000. 10 There has been a worldwide fall in the incidence of AHO.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pediatric Acute Hematogenous Osteomyelitis

Street

Puna

Huang

et al. 2015

Journal of Pediatric Orthopaedics

View full text Add to dashboard Cite

show abstract

“…We report a male predominance and a higher prevalence of BJIs among boys of all ages. Skin infections and trauma have been shown to be risk factors for BJIs in childhood (7,10,15). We also found that males had more skin disorders and fractures than females.…”

Section: Discussionmentioning

confidence: 99%

Paediatric bone and joint infections are more common in boys and toddlers: a national epidemiology study

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Neonatal vascular anatomy allows infection within the bone to reach the growth plate or joint in 76% of neonatal osteomyelitis cases. 13 The pathogens implicated in paediatric bone and joint infections commonly include meticillin-sensitive Staphylococcus aureus (MSSA) (44-80%) 8,14,15 and Kingella kingae (14-50%; higher in children aged < 36 months) 8,[15][16][17][18][19] and more rarely meticillin-resistant S. aureus (MRSA) (rare in the UK but found in 40-50% of cases in the USA), 20,21 Panton-Valentine leukocidin (PVL) MSSA, 22,23 group A Streptococcus (GAS), group B Streptococcus (GBS) (neonates), 12,24 non-typeable Haemophilus spp. (incidence unknown), Haemophilus influenzae type b (in non-immunised or immunodeficient children), Escherichia coli (neonates), 12,24 Streptococcus pneumoniae 25 and coagulase-negative Staphylococcus (subacute).…”

Section: Osteomyelitis and Septic Arthritis In Childrenmentioning

confidence: 99%

“…Radiographic changes are frequently seen in subacute OM, but can be confused with malignancies such as Ewing's sarcoma or osteoid osteoma. 13 In SA, plain radiographs are of limited use. In discitis, lateral radiographs of the spine 2-3 weeks into the illness often will reveal disc space narrowing with erosion of the vertebral end plates of the contiguous vertebrae.…”

Section: Imagingmentioning

confidence: 99%

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Sukhtankar

Arch

Ahmad

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Saul N Faust was UK chief investigator and University Hospital Southampton NHS Foundation Trust principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All funds were paid into accounts within the NHS trust or university and not paid as personal fees. He reports consultancy fees for advisory board participation paid into accounts within the NHS trust or university (not personal fees) from vaccine manufacturers and antimicrobial agent manufacturers, including AstraZeneca, Cubist, Merck, GlaxoSmithKline (GSK) and Pfizer, outside the submitted work. He acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/ University of Southampton that are sponsored by vaccine manufacturers and antimicrobial agents, and has participated in advisory boards for vaccine manufacturers. Adam Finn reports grants and personal fees from Sanofi Pasteur MSD Ltd (SPMSD), and grants and personal fees from GSK, outside the submitted work. In addition, prior to October 2014, the University of Bristol and University Hospitals Bristol NHS Foundation Trust received funding for research conducted by Adam Finn and for consultancy and lectures from Pfizer, GSK, SPMSD and Novartis, who manufacture licensed and developmental meningococcal vaccines. Stuart C Clarke acts as principal investigator for clinical trials and other studies conducted on behalf of University Hospital Southampton NHS Foundation Trust/University of Southampton that are sponsored by vaccine manufacturers but receive no personal payments from them. He has participated in advisory boards for vaccine manufacturers and has received financial assistance from vaccine manufacturers to attend conferences, but receives no personal payments for this work. All grants and honoraria are paid into accounts within the respective NHS trusts or universities. Jethro Herberg reports that he was an investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis; he received no personal payments. Andrew Riordan reports that the trust, but not he, has received funding for research sponsored by vaccine manufacturers and antimicrobial agents. He was lead editor for an e-learning package on meningitis produced by the Royal College of Paediatric and Child Health, funded by an unrestricted grant from Novartis Vaccines. Marieke Emonts was Newcastle upon Tyne Hospitals Foundation Trust's principal investigator for a Cubist-sponsored clinical trial of daptomycin against standard of care antibiotic therapy in paediatric osteomyelitis. All grants and honoraria are paid into accounts within the NHS trust or university; she received no personal payment of any kind. Marieke Emonts reports acting as site principle investigator on behalf of the Newcastle upon Tyne Hospitals Foundation Trust/Newcastle University for clinical tr...

show abstract

Haematogenous osteomyelitis in children: epidemiology, classification, aetiology and treatment

Cited by 19 publications

References 45 publications

Pediatric Acute Hematogenous Osteomyelitis

Pediatric Acute Hematogenous Osteomyelitis

Paediatric bone and joint infections are more common in boys and toddlers: a national epidemiology study

Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study

Contact Info

Product

Resources

About